Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments.

Cancers (Basel) · 2021 · PMC8616515 · PMID 34830927

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Overall survival data were not mature, however, there was a strong trend towards an improved OS in the pyrotinib arm (HR 0.46; 95% CI 0.22–0.99).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.